Core Insights - Medtronic plc reported a strong Q2 FY26 with revenue of $9.0 billion, reflecting a 6.6% increase as reported and 5.5% organic growth, exceeding guidance midpoint by 75 basis points [1] - The company raised its FY26 guidance to 5.5% organic revenue growth and adjusted EPS of $5.62-$5.66 [1] - Cardiac Ablation Solutions experienced significant growth of 71%, with a remarkable 128% increase in the U.S., driven by the pulsed field ablation (PFA) portfolio [1] Financial Performance - GAAP diluted EPS increased by 8% to $1.07, while non-GAAP diluted EPS also rose by 8% to $1.36, both above guidance [1] - The cardiovascular segment achieved its strongest revenue growth in over a decade, excluding pandemic effects [1] Product Developments - The company received broad favorable National Coverage Determination (NCD) from U.S. Centers for Medicare & Medicaid Services (CMS) for the Symplicity™ procedure, targeting an addressable market of 18 million people with uncontrolled hypertension [1] - Medtronic secured U.S. FDA approval for the Altaviva™ device, aimed at treating urge urinary incontinence, which affects over 16 million people in the U.S. [1] - The Hugo™ robotic-assisted surgery system met safety and effectiveness endpoints in the Enable Hernia Repair study and initiated the Embrace Gynecology US pivotal study [1] - The U.S. FDA cleared the MiniMed™ 780G system for integration with the Instinct sensor and approved its use in Type 2 diabetes [1]